SCHEMBL3863768

SCHEMBL3863768

Cc1ccc2[nH]c3c(cc(-c4sc5ccccc5c4C)c(=O)n3C)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ MDH2 P40926 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ MAPT P10636 5/20 0.36
▸ KDM4E B2RXH2 5/20 0.36
▸ LMNA P02545 4/20 0.36
▸ HSD17B10 Q99714 3/20 0.36
▸ HPGD P15428 3/20 0.36
▸ TP53 P04637 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ CCNB2 O95067 1/20 0.35
▸ CDK1 P06493 1/20 0.35
▸ CCNB1 P14635 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ CDK5 Q00535 1/20 0.35
▸ CDK5R1 Q15078 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3445134 0.82 NPC1 (0.41) MEN1KMT2ANPC1POLBMDH2
SCHEMBL3867849 0.80 KDM4E (0.50) MEN1KMT2ANPC1POLBMDH2
SCHEMBL3863484 0.79 KDM4E (0.39) MEN1KMT2ANPC1POLBSMN1; SMN2
SCHEMBL3444795 0.77 ALDH1A1 (0.38) MEN1KMT2ANPC1POLBSMN1; SMN2
SCHEMBL2384546 0.76 ALDH1A1 (0.41) MEN1KMT2ANPC1POLBSMN1; SMN2
SCHEMBL2383613 0.76 ALDH1A1 (0.41) MEN1KMT2ANPC1POLBMDH2
SCHEMBL3444631 0.75 KDM4E (0.43) MEN1KMT2ANPC1POLBSMN1; SMN2
SCHEMBL2385374 0.73 KDM4E (0.41) MEN1KMT2ANPC1POLBMDH2
SCHEMBL2383356 0.73 ALDH1A1 (0.43) MEN1KMT2ANPC1POLBSMN1; SMN2
SCHEMBL2381110 0.73 MAPK1 (0.43) MEN1KMT2ANPC1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042924-A1 Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics SANOFI-AVENTIS (FR) 2009-02-12 — — US claimed
US-7456193-B2 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-11-25 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042924-A1 Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics PNPO, DPYD, PDXK MEN1 860/4885KMT2A 3907/4885NPC1 3973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback